Astrazeneca (AZN) Long-Term Debt Issuances (2009 - 2021)

Astrazeneca has reported Long-Term Debt Issuances for 10 years, with the latest figure at $15.9 billion in Q4 2021.

• On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $15.9 billion in Q4 2021; TTM through Dec 2021 was $12.9 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $15.0 million, down 99.77% from the prior year.
• Long-Term Debt Issuances was $15.9 billion for Q4 2021 at Astrazeneca, up from -$10.9 billion in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $15.9 billion in Q4 2021, with the low at -$10.9 billion in Q3 2021.
• Average Long-Term Debt Issuances over 4 years is $856.6 million, with a median of $248.0 million recorded in 2019.
• The sharpest annual moves came in 2017 and 2018: Long-Term Debt Issuances sank 366.67% in 2017, then soared 179.48% in 2018.
• Over 4 years, Long-Term Debt Issuances stood at -$3.7 billion in 2017, then declined by 16.89% to -$4.4 billion in 2018, then surged by 145.72% to $2.0 billion in 2019, then surged by 693.15% to $15.9 billion in 2021.
• The last three Long-Term Debt Issuances figures came in at $15.9 billion (Q4 2021), -$10.9 billion (Q3 2021), and $7.9 billion (Q2 2021), per Business Quant data.